Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: Experimental studies in pigs

Susan E. Grauer, George A. Pantely, Jinping Xu, Shuping Ge, George D. Giraud, Takahiro Shiota, David J. Sahn

    Research output: Contribution to journalArticlepeer-review

    23 Scopus citations

    Abstract

    The development of echo contrast agents that can provide reliable opacification of the myocardium after intravenous injection is an important advancement for the clinical application of contrast echocardiography. In this study, the hemodynamic effects and echocardiographic characteristics of a new lipid-fluorocarbon echo contrast agent, Aerosomes MRX 115 (ImaRx Pharmaceutical Corp., Tucson, Ariz.) were studied in six anesthetized ventilated pigs. Intravenous injection of this new agent in doses ranging from 0.0005 to 0.01 ml/kg produced significant measurable and visible myocardial opacification without any effect on heart rate, systemic pressure, partial pressure of oxygen, or left ventricular systolic function. The two largest doses (0.005 and 0.01 ml/kg), however, resulted in mild reversible increases in mean pulmonary artery pressure of 12 and 16 mm Hg, respectively. In four animals, epicardial images were obtained before and during coronary artery occlusion. Intravenous contrast injection during coronary occlusion permitted delineation of the hypoperfused myocardial segment. This capability may further expand the utility of contrast echocardiography.

    Original languageEnglish (US)
    Pages (from-to)938-945
    Number of pages8
    JournalAmerican heart journal
    Volume132
    Issue number5
    DOIs
    StatePublished - 1996

    ASJC Scopus subject areas

    • Cardiology and Cardiovascular Medicine

    Fingerprint

    Dive into the research topics of 'Myocardial imaging with a new transpulmonary lipid-fluorocarbon echo contrast agent: Experimental studies in pigs'. Together they form a unique fingerprint.

    Cite this